Medicure Inc (TSXV:MPH) (OTC:MCUJF), a cardiovascular pharmaceutical company, announced on Wednesday its financial results for the nine months ended 30 September 2020.
The company's reported adjusted EBITDA for the nine months ended 30 September 2020 was negative USD1m, compared to negative USD1.9m for the same period in 2019.
The firm posted net loss for the nine months ended 30 September 2020 at USD2.5m or USD0.23 per share, compared to a net loss of USD4.3m or USD0.28 per share for the nine months ended 30 September 2019.
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal
Sarepta Therapeutics commences Phase 3 clinical study of SRP-9003 for LGMD2E